iFAST is developing a game-changing, rapid antimicrobial susceptibility test, that will enable every patient with bacterial infections to receive the right antibiotic, on time, every time. Currently, these tests take 48-72 hours, but iFAST's tests are 10x faster - giving full quantitative and qualitative results in under 3 hours from a positive blood culture or bacterial isolate. The technology is cheaper and involve less tedious manual labour than current standard of care, which is based on technology from the mid-1900s! We also offer high throughout (most labs only need one system to accommodate all their requirements). This is a $4bn market and we will be launching on the UK market at the start of 2026, and in the US and EU the following year.
| Website | https://ifastdiagnostics.com/ |
| Employees | 28 (17 on RocketReach) |
| Founded | 2022 |
| Phone | +44 7788 595176 |
| Industry | Medical and Diagnostic Laboratories |
| Keywords | Antimicrobial Susceptibility Testing, Antibiotic Resistance Testing, Rapid Diagnostic Tests, Rapid Diagnostics, Infectious Disease Diagnostics, Microbial Diagnostics, Infection Diagnostics, Point-Of-Care Diagnostics, Microbiology Testing, Pathogen Detection, Clinical Microbiology, Molecular Diagnostics, Infection Control, Diagnostics Testing, Personalized Medicine, Healthcare Diagnostics |
| Competitors | Oracle Health Information, Siemens, Roche, Thermo Fisher Scientific, Abbott, Quest Diagnostics, Labcorp, PerkinElmer, Inc., BioReference Laboratories, Medtox Laboratories +39 more (view full list) |
Looking for a particular iFAST Diagnostics employee's phone or email?
Toby King is the CEO of iFAST Diagnostics.
17 people are employed at iFAST Diagnostics.
iFAST Diagnostics is based in Southampton, England.